Memantine induces reversible neurologic impairment in patients with MS
Abstract
Background: Cognitive dysfunction is very common in multiple sclerosis (MS) and it severely impairs patients’ quality of life. Thus, we explored whether memantine might improve cognitive performance in patients with MS.
Methods: We conducted a pilot trial with memantine (30 mg/day) in patients with MS with cognitive impairment. The trial was designed as a 1-year, randomized, double-blind, crossover study comparing memantine against a placebo in 60 patients with MS and cognitive impairment. Cognitive impairment was defined as the performance 1.5 standard deviations below the normative data in at least two tests of two cognitive domains in the Brief Repeatable Battery–Neuropsychology. The primary endpoint was improvement of verbal memory and the secondary endpoints were safety and improvements in the other cognitive domains, disability and quality of life. The trial was registered at www.clinicaltrials.org: NCT00638833.
Results: Although 19 patients had been included, the trial was halted after nine patients reported a worsening of their neurologic symptoms that deteriorated their quality of life. Seven of the nine patients in the memantine arm had blurred vision, fatigue, severe headache, increased muscle weakness, walking difficulties, or unstable gait. Only two patients in the placebo group reported neurologic symptoms and in both cases they were related with changes in their disease-modifying therapy. The adverse events only occurred on reaching the maximum dose (30 mg/day). After stopping medication, the patients reverted to their baseline disability within a few days.
Conclusions: Memantine at a dose of 30 mg/day may induce transient worsening of neurologic symptoms of multiple sclerosis.
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES
1.
Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci 2006;245:41–46.
2.
Sepulcre J, Vanotti S, Hernandez R, et al. Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test. Mult Scler 2006;12:187–195.
3.
Duque B, Sepulcre J, Bejarano B, et al. Memory decline evolves independently of disease activity in MS. Mult Scler 2008;14:947–953.
4.
Amato MP, Goretti B, Ghezzi A, et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology 2008;70:1891–1897.
5.
Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006;1–11.
6.
Starck M, Albrecht H, Pollmann W, et al. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol 1997;244:9–16.
7.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.
8.
Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244–250.
9.
Fischer JS, LaRocca NG, Miller DM, et al. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 1999;5:251–259.
10.
Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005;58:840–846.
11.
Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48:S10–16.
12.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
13.
Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977;21:247–254.
14.
Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 1999;354:1649–1673.
15.
Wegner C, Filippi M, Korteweg T, et al. Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol 2008;15:113–122.
16.
Waxman SG. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci 2006;7:932–941.
17.
Stys PK, Lipton SA. White matter NMDA receptors: an unexpected new therapeutic target? Trends Pharmacol Sci 2007;28:561–566.
Information & Authors
Information
Published In
Copyright
© 2009.
Publication History
Published online: December 17, 2008
Published in print: May 12, 2009
Notes
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Gene Regulation by Nuclear Calcium and Its Antagonism by NMDAR/TRPM4 Signaling, Transcriptional Regulation by Neuronal Activity, (113-170), (2024).https://doi.org/10.1007/978-3-031-68550-7_4
- The Disruption of NMDAR/TRPM4 Death Signaling with TwinF Interface Inhibitors: A New Pharmacological Principle for Neuroprotection, Pharmaceuticals, 16, 8, (1085), (2023).https://doi.org/10.3390/ph16081085
- Multiple sclerosis: Motor dysfunction, Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment, (119-147), (2023).https://doi.org/10.1016/B978-0-323-98817-9.00016-8
- Multiple sclerosis: Inflammation, autoimmunity and plasticity, Neuroplasticity - From Bench to Bedside, (457-470), (2022).https://doi.org/10.1016/B978-0-12-819410-2.00024-2
- Memantine for Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Trials, Frontiers in Neurology, 11, (2021).https://doi.org/10.3389/fneur.2020.574748
- Neuroprotective Methodologies in the Treatment of Multiple Sclerosis Current Status of Clinical and Pre-clinical Findings, Current Drug Discovery Technologies, 18, 1, (31-46), (2021).https://doi.org/10.2174/1570163817666200207100903
- Oligodendrocytes, BK channels and the preservation of myelin, F1000Research, 10, (781), (2021).https://doi.org/10.12688/f1000research.53422.2
- Oligodendrocytes, BK channels and remyelination, F1000Research, 10, (781), (2021).https://doi.org/10.12688/f1000research.53422.1
- A pilot study of oxidative pathways in MS fatigue: randomized trial of N‐acetyl cysteine, Annals of Clinical and Translational Neurology, 8, 4, (811-824), (2021).https://doi.org/10.1002/acn3.51325
- Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis–related fatigue, Multiple Sclerosis Journal, 27, 6, (942-953), (2020).https://doi.org/10.1177/1352458520936226
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.